Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 13/20 | 0.75 |
| ▸ | MMP1 | P03956 | 10/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.74 |
| ▸ | PGR | P06401 | 5/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.72 |
| ▸ | AR | P10275 | 2/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | APEX1 | P27695 | 1/20 | 0.72 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.72 |
| ▸ | IKBKB | O14920 | 1/20 | 0.72 |
| ▸ | CHUK | O15111 | 1/20 | 0.72 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.72 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337332 | 1.00 | NR3C1 (0.75) | NR3C1MMP1CYP3A4PGRMEN1 | |
| SCHEMBL1048586 | 1.00 | NR3C1 (0.75) | NR3C1MMP1CYP3A4PGRMEN1 | |
| SCHEMBL15568326 | 0.95 | NR3C1 (0.73) | NR3C1MMP1CYP3A4PGRMEN1 | |
| SCHEMBL2898449 | 0.93 | NR3C1 (0.76) | NR3C1MMP1CYP3A4PGRMEN1 | |
| SCHEMBL15671680 | 0.93 | NR3C1 (0.76) | NR3C1MMP1CYP3A4PGRMEN1 | |
| SCHEMBL73249 | 0.93 | NR3C1 (0.76) | NR3C1MMP1CYP3A4PGRMEN1 | |
| Water SCHEMBL201856 | 0.92 | NR3C1 (0.75) | NR3C1MMP1CYP3A4PGRMEN1 | |
| SCHEMBL2123848 | 0.92 | NR3C1 (0.75) | NR3C1MMP1CYP3A4PGRMEN1 | |
| SCHEMBL3836633 | 0.92 | NR3C1 (0.75) | NR3C1MMP1CYP3A4PGRMEN1 | |
| SCHEMBL3126388 | 0.92 | NR3C1 (0.75) | NR3C1MMP1CYP3A4PGRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144067-A1 | PERSONALIZED STARVATION THERAPY FOR CANCER | FAETH THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| WO-2025091017-A1 | SYNTHETIC WHOLE BLOOD SUBSTITUTES | OHIO STATE INNOVATION FOUNDATION (US) | 2025-05-01 | — | — | WO | disclosed |
| US-12011450-B2 | Polyethylene glycol-conjugated glucocorticoid prodrugs and compositions and methods thereof | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2024-06-18 | — | — | US | disclosed |
| US-20240165130-A1 | COMPOSITE DRUG PARTICLES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-05-23 | — | — | US | disclosed |
| CN-117956981-A | Controlled release dosage form for medicine in tympanic cavity containing N-acylated glycol chitosan | 中南大学的产学研合作 | 2024-04-30 | — | — | CN | disclosed |
| EP-4312991-A1 | COMPOSITE DRUG PARTICLES AND USES THEREOF | The Regents Of The University Of Michigan (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20240000800-A1 | Polyethylene Glycol-Conjugated Glucocorticoid Prodrugs and Compositions and Methods Thereof | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2024-01-04 | — | — | US | disclosed |
| WO-2023224213-A1 | DRUG DELIVERY SYSTEM, PHARMACEUTICAL COMPOSITION FOR TREATING EAR DISEASES INCLUDING SAME, AND CONTROLLED DRUG RELEASE FORMULATION | 충남대학교산학협력단 | 2023-11-23 | — | — | WO | disclosed |
| EP-3696185-A9 | POLYETHYLENE GLYCOL-CONJUGATED GLUCOCORTICOID PRODRUGS AND COMPOSITIONS AND METHODS THEREOF | Board of Regents of the University of Nebraska (US) | 2023-05-03 | — | — | EP | disclosed |
| WO-2023054951-A1 | INTRATYMPANIC DRUG CONTROLLED RELEASE-TYPE FORMULATION COMPRISING N-ACYLATED GLYCOL CHITOSAN | 충남대학교산학협력단 | 2023-04-06 | — | — | WO | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| WO-2002007683-A1 | ANTIMICOTIC NAIL VARNISH COMPOSITION | POLICHEM S.A. (LU) | 2002-01-31 | — | — | WO | disclosed |
| CN-1310613-A | Rapidly disintegrable solid preparation | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-08-29 | — | — | CN | disclosed |
| US-6274118-B1 | INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE | NORDION INTERNATIONAL INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| CN-1282263-A | Anhydrous drug reservoir for electrolytic transdermal delivery device | ALZA CORP (US) | 2001-01-31 | — | — | CN | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
| CN-1265585-A | (imidazol-5-yl) methyl-2-quinolinone derivatives as smooth muscle cell proliferation inhibitors | JANSSEN PHARMACEUTICA NV (NL) | 2000-09-06 | — | — | CN | disclosed |
| CN-1237901-A | Protein-stabilized pharmacologically active agents and methods for their preparation and use | VIVORX PHARMACEUTICALS INC (US) | 1999-12-08 | — | — | CN | disclosed |
| CN-1215986-A | Method for preparing gas-filled liposomes | IMARX PHARMACEUTICAL CORP (US) | 1999-05-05 | — | — | CN | disclosed |
| WO-1995002424-A1 | LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN | NORDION INTERNATIONAL INC. (CA) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165130-A1 | COMPOSITE DRUG PARTICLES AND USES THEREOF | LIPC, LIPA, FABP4 | NR3C1 108/4885MMP1 1358/4885CYP3A4 193/4885 |
| US-12011450-B2 | Polyethylene glycol-conjugated glucocorticoid prodrugs and compositions and methods thereof | NR3C1, SSB, SERPINA6 | NR3C1 1/4885MMP1 1755/4885CYP3A4 1703/4885 |
| US-20240000800-A1 | Polyethylene Glycol-Conjugated Glucocorticoid Prodrugs and Compositions and Methods Thereof | NR3C1, SSB, SERPINA6 | NR3C1 1/4885MMP1 1755/4885CYP3A4 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.